ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT)QR-421a observed to be well tolerated with no serious adverse events reportedTwo pivotal Phase 2/3 trials...Read More

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma First Anti-PD-1 in Combination With Chemotherapy Approved for the First-Line Treatment of Esophageal and GEJ Carcinoma, Regardless of Histology or PD-L1 Expression KENILWORTH, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known...Read More

Results from a phase 3 clinical trial show that Regeneron’s antibody cocktail has the ability to cut the risk of COVID-19 hospitalization and death by 70 percent.The treatment also shortened the duration of COVID-19 symptoms by 4 days.The two antibodies work similarly to the antibodies the immune system naturally produces to fight the coronavirus. Regeneron’s...Read More

Creating a world leader in Healthcare Intelligence and Clinical Research The consolidation brings together two organizations with a history of robust growth and performance ready to build on this strength using the outstanding talent of both companies to deliver enhanced value to patients, customers, employees and shareholders.All customers will benefit from increased functional, geographic and...Read More